Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5561672 | 0.88 | IDO1 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL31124717 | 0.84 | TRPA1 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2TACR1 | |
| SCHEMBL2901818 | 0.84 | AR (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1314001 | 0.83 | AGXT (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL501339 | 0.83 | TACR1 (0.32) | SMYD2CYP3A4HTTSMN1; SMN2TACR1 | |
| SCHEMBL4587307 | 0.83 | IDO1 (0.42) | HTTSMN1; SMN2 | |
| SCHEMBL6936162 | 0.82 | IDO1 (0.49) | — | |
| SCHEMBL29910773 | 0.82 | IDO1 (0.49) | — | |
| SCHEMBL1853659 | 0.81 | AKR1B1 (0.34) | CYP3A4HTTSMN1; SMN2TACR1 | |
| SCHEMBL31124766 | 0.81 | TSHR (0.35) | SMYD2CYP3A4HTTSMN1; SMN2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3983409-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008044-A | Pyridyl or pyrimidinyl MTOR kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020249652-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | MTOR, RICTOR, RPTOR | SMYD2 2434/4885CYP3A4 2267/4885HTT 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.